| Year |
Citation |
Score |
| 2023 |
Wogu AF, Li H, Zhao S, Nichols HB, Cai J. Additive subdistribution hazards regression for competing risks data in case-cohort studies. Biometrics. PMID 36606409 DOI: 10.1111/biom.13821 |
0.397 |
|
| 2020 |
Prentice RL, Zhao S. Regression Models and Multivariate Life Tables. Journal of the American Statistical Association. 116: 1330-1345. PMID 34629570 DOI: 10.1080/01621459.2020.1713792 |
0.556 |
|
| 2020 |
Wang M, Wasserman E, Geyer N, Carroll RM, Zhao S, Zhang L, Hohl R, Lengerich EJ, McDonald AC. Spatial patterns in prostate Cancer-specific mortality in Pennsylvania using Pennsylvania Cancer registry data, 2004-2014. Bmc Cancer. 20: 394. PMID 32375682 DOI: 10.1186/S12885-020-06902-5 |
0.302 |
|
| 2020 |
Prentice RL, Aragaki AK, Chlebowski RT, Zhao S, Anderson GL, Rossouw JE, Wallace R, Banack H, Shadyab AH, Qi L, Snively BM, Gass M, Manson JAE. Response to Commentary on 'Dual Outcome Intention-To-Treat Analyses in the Women's Health Initiative Randomized Controlled Hormone Therapy Trials'. American Journal of Epidemiology. PMID 32314786 DOI: 10.1093/Aje/Kwaa032 |
0.568 |
|
| 2020 |
Prentice RL, Aragaki AK, Chlebowski RT, Zhao S, Anderson GL, Rossouw JE, Wallace R, Banack H, Shadyab AH, Qi L, Snively BM, Gass M, Manson JAE. Dual Outcome Intention-to-treat Analyses in the Women's Health Initiative Randomized Controlled Hormone Therapy Trials. American Journal of Epidemiology. PMID 32314781 DOI: 10.1093/Aje/Kwaa033 |
0.586 |
|
| 2019 |
Cheng A, Zhao S, FitzGerald LM, Wright JL, Kolb S, Karnes RJ, Jenkins RB, Davicioni E, Ostrander EA, Feng Z, Fan JB, Dai JY, Stanford JL. A four-gene transcript score to predict metastatic-lethal progression in men treated for localized prostate cancer: Development and validation studies. The Prostate. PMID 31376183 DOI: 10.1002/Pros.23882 |
0.3 |
|
| 2018 |
Zhao S, Leonardson A, Geybels MS, McDaniel AS, Yu M, Kolb S, Zong H, Carter K, Siddiqui J, Cheng A, Wright JL, Pritchard CC, Lance R, Troyer D, Fan JB, et al. A five-CpG DNA methylation score to predict metastatic-lethal outcomes in men treated with radical prostatectomy for localized prostate cancer. The Prostate. PMID 29956356 DOI: 10.1002/Pros.23667 |
0.31 |
|
| 2018 |
Carroll R, Lawson AB, Zhao S. Temporally dependent accelerated failure time model for capturing the impact of events that alter survival in disease mapping. Biostatistics (Oxford, England). PMID 29939209 DOI: 10.1093/Biostatistics/Kxy023 |
0.3 |
|
| 2017 |
Rubicz R, Zhao S, Wright JL, Coleman I, Grasso C, Geybels MS, Leonardson A, Kolb S, April C, Bibikova M, Troyer D, Lance R, Lin DW, Ostrander EA, Nelson PS, et al. Gene expression panel predicts metastatic-lethal prostate cancer outcomes in men diagnosed with clinically localized prostate cancer. Molecular Oncology. 11: 140-150. PMID 28145099 DOI: 10.1002/1878-0261.12014 |
0.309 |
|
| 2016 |
Prentice RL, Zhao S. Nonparametric estimation of the multivariate survivor function: the multivariate Kaplan-Meier estimator. Lifetime Data Analysis. PMID 27677472 DOI: 10.1007/S10985-016-9383-Y |
0.445 |
|
| 2016 |
Geybels MS, Wright JL, Bibikova M, Klotzle B, Fan JB, Zhao S, Feng Z, Ostrander EA, Lin DW, Nelson PS, Stanford JL. Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy. Clinical Epigenetics. 8: 97. PMID 27651837 DOI: 10.1186/S13148-016-0260-Z |
0.304 |
|
| 2016 |
Zhao S, Geybels MS, Leonardson A, Rubicz R, Kolb S, Yan Q, Klotzle B, Bibikova M, Hurtado-Coll A, Troyer D, Lance R, Lin D, Wright JL, Ostrander EA, Fan JB, et al. Epigenome-wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-lethal Progression in Men with Clinically Localized Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27358489 DOI: 10.1158/1078-0432.Ccr-16-0549 |
0.305 |
|
| 2016 |
Rubicz R, Zhao S, Geybels M, Wright JL, Kolb S, Klotzle B, Bibikova M, Troyer D, Lance R, Ostrander EA, Feng Z, Fan JB, Stanford JL. DNA methylation profiles in African American prostate cancer patients in relation to disease progression. Genomics. PMID 26902887 DOI: 10.1016/J.Ygeno.2016.02.004 |
0.307 |
|
| 2015 |
Zhao S, Prentice RL. Rejoinder to "On the Misuse of Taylor Expansion". Biometrics. 71: 1195. PMID 26769150 DOI: 10.1111/Biom.12426 |
0.382 |
|
| 2015 |
Zhao S, Zheng Y, Prentice RL, Feng Z. Two-stage biomarker panel study and estimation allowing early termination for futility. Biostatistics (Oxford, England). 16: 799-812. PMID 25964662 DOI: 10.1093/Biostatistics/Kxv017 |
0.466 |
|
| 2014 |
Zhao S, Prentice RL. Covariate measurement error correction methods in mediation analysis with failure time data. Biometrics. 70: 835-44. PMID 25139469 DOI: 10.1111/Biom.12205 |
0.477 |
|
| 2014 |
Stott-Miller M, Zhao S, Wright JL, Kolb S, Bibikova M, Klotzle B, Ostrander EA, Fan JB, Feng Z, Stanford JL. Validation study of genes with hypermethylated promoter regions associated with prostate cancer recurrence. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 23: 1331-9. PMID 24718283 DOI: 10.1158/1055-9965.Epi-13-1000 |
0.305 |
|
| 2014 |
Zhao S, Chlebowski RT, Anderson GL, Kuller LH, Manson JE, Gass M, Patterson R, Rohan TE, Lane DS, Beresford SA, Lavasani S, Rossouw JE, Prentice RL. Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects. Breast Cancer Research : Bcr. 16: R30. PMID 24670297 DOI: 10.1186/Bcr3632 |
0.471 |
|
| 2013 |
Prentice RL, Zhao S, Johnson M, Aragaki A, Hsia J, Jackson RD, Rossouw JE, Manson JE, Hanash SM. Proteomic risk markers for coronary heart disease and stroke: validation and mediation of randomized trial hormone therapy effects on these diseases. Genome Medicine. 5: 112. PMID 24373343 DOI: 10.1186/Gm517 |
0.459 |
|
| Show low-probability matches. |